Loading clinical trials...
Loading clinical trials...
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
Collaborators
NCT07301736 · Asthma
NCT06732141 · Asthma
NCT06932263 · Asthma
NCT07245576 · Asthma, COPD
NCT07160868 · Asthma (Diagnosis), OSA - Obstructive Sleep Apnea, and more
This study is not being conducted in the United States
Tokyo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions